We are live on ! Find out more
VC

Vivo Capital Portfolio holdings

AUM $1.2B
1-Year Est. Return 911.44%
This Fund
S&P 500
This Quarter Est. Return
+78.01%
1 Year Est. Return
+911.44%
3 Year Est. Return
+7,373.93%
5 Year Est. Return
+10,475.15%
10 Year Est. Return
+136,503.27%
AUM
$1.2B
AUM Growth
-$344M
Cap. Flow
-$568M
Cap. Flow %
-47.21%
Top 10 Hldgs %
59.33%
Holding
55
New
8
Increased
5
Reduced
9
Closed
9

Top Buys

Rank Stock Value
1
ERAS icon
Erasca
ERAS
+$34M
2
AVBP icon
ArriVent BioPharma
AVBP
+$20M
3
MANE
Veradermics Inc
MANE
+$15.1M
4
FTH
Faeth Therapeutics
FTH
+$14.4M
5
CRVS icon
Corvus Pharmaceuticals
CRVS
+$9.12M

Top Sells

Rank Stock Value
1
CDTX
Cidara Therapeutics
CDTX
+$211M
2
TERN
Terns Pharmaceuticals
TERN
+$165M
3
COGT icon
Cogent Biosciences
COGT
+$73M
4
AVDL
Avadel Pharmaceuticals
AVDL
+$57.8M
5
ZBIO
Zenas BioPharma
ZBIO
+$31M

Sector Composition

Rank Sector Weight
1 Healthcare 100%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
COGT icon
26
Cogent Biosciences
COGT
$6.95B
$16.3M 1.35%
422,300
-1,976,693
-82% -$73M
GERN icon
27
Geron
GERN
$930M
$12.9M 1.07%
8,671,797
-18,553,495
-68% -$28.2M
UNCY icon
28
Unicycive Therapeutics
UNCY
$135M
$11.8M 0.98%
1,789,916
– –
ANTX icon
29
AN2 Therapeutics
ANTX
$169M
$10.8M 0.9%
+3,153,640
New +$6.51M
OLMA icon
30
Olema Pharmaceuticals
OLMA
$1.01B
$10M 0.83%
671,843
– –
SLNO
31
DELISTED
Soleno Therapeutics
SLNO
$9.87M 0.82%
294,909
-600,000
-67% -$23.5M
EPRX
32
Eupraxia Pharmaceuticals
EPRX
$398M
$9.77M 0.81%
1,350,000
– –
OKUR
33
OnKure Therapeutics
OKUR
$160M
$7.98M 0.66%
+1,927,710
New +$5.95M
SRZN icon
34
Surrozen
SRZN
$225M
$7.57M 0.63%
260,000
– –
ALXO icon
35
ALX Oncology
ALXO
$268M
$6.39M 0.53%
+3,184,713
New +$6.07M
MNPR icon
36
Monopar Therapeutics
MNPR
$731M
$4.96M 0.41%
90,500
– –
MSLE
37
Satellos Bioscience
MSLE
$197M
$4.58M 0.38%
+813,666
New +$7.99M
PEPG icon
38
PepGen
PEPG
$127M
$4.12M 0.34%
2,325,000
– –
SERA icon
39
Sera Prognostics
SERA
$79.5M
$3.35M 0.28%
1,650,440
– –
TENX icon
40
Tenax Therapeutics
TENX
$419M
$3.33M 0.28%
208,333
– –
VRDN icon
41
Viridian Therapeutics
VRDN
$2.15B
$3.25M 0.27%
166,288
-816,288
-83% -$24.2M
TIL icon
42
Instil Bio
TIL
$49.4M
$2.41M 0.2%
292,743
– –
KTTA icon
43
Pasithea Therapeutics
KTTA
$15M
$1.56M 0.13%
2,100,000
– –
CMPS
44
Compass Pathways
CMPS
$1.46B
$1.11M 0.09%
+200,000
New +$1.35M
BOLT icon
45
Bolt Biotherapeutics
BOLT
$7.72M
$293K 0.02%
72,414
– –
DTIL icon
46
Precision BioSciences
DTIL
$185M
$25.7K ﹤0.01%
4,675
– –
ABEO icon
47
Abeona Therapeutics
ABEO
$343M
– –
-1,842,751
Closed -$9.71M
AVDL
48
DELISTED
Avadel Pharmaceuticals
AVDL
– –
-2,684,109
Closed -$57.8M
CDTX
49
DELISTED
Cidara Therapeutics
CDTX
– –
-956,670
Closed -$211M
CTMX icon
50
CytomX Therapeutics
CTMX
$701M
– –
-2,884,615
Closed -$12.3M
1
2
3

Similar funds

SGDR
SPX Gestao de Recursos Rio De Janeiro, Brazil $1.2B AUM 59.05% 1-Year Est. Return
FCCPG
FountainVest China Capital Partners GP3 Grand Cayman, Cayman Islands $1.2B AUM 6.95% 1-Year Est. Return
GP
Guardian Partners Toronto, Canada $1.2B AUM 35.94% 1-Year Est. Return
RCYC
Richard C. Young & Co Newport, Rhode Island $1.21B AUM 38.41% 1-Year Est. Return
AIM
Anchor Investment Management Columbia, South Carolina $1.2B AUM 17.33% 1-Year Est. Return
CA
Callahan Advisors Houston, Texas $1.2B AUM 22.34% 1-Year Est. Return
SC
Shay Capital New York $1.2B AUM 37.47% 1-Year Est. Return
HCM
Hodges Capital Management Dallas, Texas $1.21B AUM 49% 1-Year Est. Return

Vivo Capital's Q1 2026 Portfolio in Review

As of Q1 2026, Vivo Capital held 55 positions worth $1.2B, down 22% from $1.55B the previous quarter. Its ten largest holdings account for 59% of the portfolio.

Vivo Capital withdrew a net $568M in Q1 2026, closing 9 positions and reducing 9 holdings. Its most notable exit was Cidara Therapeutics, an estimated $211M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 100% a quarter earlier.

Against the trend, Vivo Capital opened a new position in ArriVent BioPharma worth $20.4M.

  • Vivo Capital's largest Q1 2026 buy was ArriVent BioPharma: 885,916 shares worth $20.4M.
  • Vivo Capital added most to Erasca in Q1 2026, an estimated $34M increase.
  • Vivo Capital's biggest Q1 2026 reduction was Terns Pharmaceuticals, cutting an estimated $165M.
  • Vivo Capital fully exited Cidara Therapeutics in Q1 2026, selling an estimated $211M.
  • Vivo Capital's ten largest holdings make up 59% of its $1.2B portfolio in Q1 2026.
  • Vivo Capital opened 8 new positions and closed 9 in Q1 2026.
  • Vivo Capital's portfolio value fell 22% quarter-over-quarter to $1.2B.

Based on Vivo Capital's 13F filing for Q1 2026, filed 15 May 2026.